Pharmaceuticals, Biotechnology and Life Sciences
To reduce potential exposure to COVID-19, the U.S. Food & Drug Administration (FDA) issued temporary guidance to increase access to…
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is the world’s leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract…
WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, has extended its digital clinical trial solutions to support…
Collaboration Will Screen Human Taste Bud Cells with Small Molecule Libraries to Develop Easier Ways for Children and Adults to…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other…
Vaccine will be delivered via a dermal patch applied to skin Verndari’s VaxiPatch™ microneedle patch technology enables mass production of…
Partnership marks an important step in the growth of decentralized clinical trials PALO ALTO, Calif.–(BUSINESS WIRE)–#ECGs—Medable, Inc., the leading global…
FDA has approves Merck’s Keytruda, pembrolizumab, for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications.
Mylan and Biocon have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), as it was approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.